Trius and General Market Commentary 6/5/13.. Answering critics and explaining market cap to price. Business basics as well.
Tag: ARNA
Trius Therapeutics: The Next Big Small-Cap Biotech Mover?
Normally, I write about biotech companies with near-term catalysts I feel offer traders good long based trade opportunities heading into these catalysts. Every so often, I find a small cap biotech where I feel a speculation investment is truly warranted.…
Weekend update with some charts, Market forecast and opinion. (VIDEO)
Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video
The Obesity Epidemic – EnteroMedics New Treatment Approach
Our focus turns to EnteroMedics (NASDAQ:ETRM), which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics’ approach may be a better solution for people who see little or no…
UPDATED: EnteroMedics (ETRM) Basic DD and Thesis
EnteroMedics Inc. (ETRM) I bought a nice amount of shares. Catalyst trade run up target opinion: $.4.40. Positive data release: Gap to $7. 1 year: $15 (my opinions only) According to company press releases, conference calls, and my correspondence with…
Athersys: Upcoming Short Term Catalyst With Promising Longer Term Potential
In 2012, many stem cell stocks experienced fast-paced growth as new and promising research continues to propel the industry forward. Last July, I wrote about Pluristem Therapeutics (PSTI), a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products…
Charts and commentary on $ATHX and others + Trading analysis. Honor Dr. King today.
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. please note; the charts on the right side get cut off…
Athersys, Inc. (ATHX) Beginning Due Diligence (chart technicals to come in seperate post)
Beginning points of Due Diligence for Athersys (ATHX) I am long the stock from $1.24. My Short Term catalyst Price Target opinion is $1.55 to $1.75, and $2.75 based on if positive Phase II data is reported. Multiple 2013 Catalysts…
Neptune’s Bounce Should Continue: $3 in range
Originally posted at www.biomedreports.com Updated by StockMatusow.com Twitter @BioMedReports @ScottMatusow Neptune Technologies & Bioressources announced they will hold a conference call on Thursday, January 17th at 4:30 EST. The reason given for the call will be to discuss the third…
11/30/12 Catalyst Trade And Speculation Investment List
Alexza Pharma (NASDAQ: ALXA) Alexza engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes…
